



Pharma &amp; Chemical

Fortnightly Newsletter

1st May to 15th May 2020

## Investment and Exit

### Avendus credit fund invests in Mumbai-based drug distributor

12th May 2020. VCCircle

A fund managed by a unit of Avendus Capital Pvt. Ltd, the investment bank majority owned by private equity firm KKR, has invested... [more](#)

### CVC Capital to pick up stake in oncology chain HCG in second India deal

7th May 2020. VCCircle

Private equity firm CVC Capital Partners is set to make its second India bet by investing in oncology chain HealthCare Global Enterprises Ltd (HCG) that listed a little over four years ago.... [more](#)

### Ratan Tata invests in Generic Aadhaar to bring affordable medicines to masses

10th May 2020. Economic Times

Ratan Tata, on Thursday, invested an undisclosed amount in pharmaceutical venture Generic Aadhaar. Founded by Arjun Deshpande, the startup claims... [more](#)

### Physician engagement startup Doceree closes seed funding round of \$1 million

12th May 2020. Economic Times

Doceree Inc., a programmatic physician engagement platform, on Tuesday said it has raised \$1 million in seed funding from a group of angel investors from India and the United States.... [more](#)

## Merger and Acquisition

### Carlyle to take over SeQuent Scientific in its biggest India control deal

8th May 2020. VCCircle

Private equity firm Carlyle has agreed to acquire up to 74% of animal healthcare company SeQuent Scientific Ltd for Rs 1,580 crore (about \$210 million) in what would be its biggest control-oriented deal in India.... [more](#)

### Reliance plans to buy e-pharmacy Netmeds

6th May 2020. Economic Times

Mukesh Ambani's Reliance Industries is in advanced discussions to acquire a majority stake in online pharmacy Netmeds as part of its broader play in commerce... [more](#)

### Four PE firms close in on JB Chemicals

6th May 2020. Economic Times

Global buyout funds KKR, Carlyle, Apax Partners and PAG are in the race to acquire domestic pharmaceuticals firm JB Chemicals & Pharmaceuticals Ltd at a valuation of about Rs 5,000 crore, or \$650 million... [more](#)

### GSK sells HUL stake for Rs25,480 crore in largest secondary trade on exchanges

7th May 2020. Live Mint

GlaxoSmithKline Plc (GSK) on Thursday said it has sold its 5.7% stake in fast moving consumer goods (FMCG) major, Hindustan Unilever Ltd (HUL), for Rs25,480 crore... [more](#)

## Pharma

### Zydus Cadila launches affordable prostate cancer therapy in India

11th May 2020. Pharma Tutor

Zydus Cadila, a global innovation driven healthcare company, announced that it is launching Enzalutamide, a highly effective drug for the treatment of Prostate Cancer, under the brand name 'Obnyx' in India.... [more](#)

## Mega FDI plan to focus on faster pharma approvals

10th May 2020. [Economic Times](#)

The government has begun examining ways to shore up foreign investments, including a fast-track mechanism to clear applications of companies especially in the pharmaceutical sector that are looking at India with the US pushing its companies to relocate from China... [more](#)

## Allmpus Labs to focus on increasing R&D in new drug discovery and development

9th May 2020. [Pharma Biz](#)

Allmpus Laboratories, a research-based pharmaceutical company is planning to focus on increasing research and development in the area of new drug discovery and development directed towards diseases like inflammation, diabetes and Alzheimer... [more](#)

## Unichem Laboratories gets EIR from USFDA for Roha facility; stock surges 5.5%

5th May 2020. [IIFL](#)

Shares of Unichem Laboratories surged 5.5% on the BSE in the morning trade after the pharma company has received the Establishment Inspection Report (EIR) from USFDA for its Active Pharmaceutical Ingredients (APIs) facility at Roha... [more](#)

## Global News

### Legend Biotech Aims for \$100 Million IPO

14th May 2020. [Bio Spaces](#)

New Jersey-based Legend Biotech, a clinical stage oncology biotech company, filed with the U.S. Securities and Exchange Commission on Wednesday to raise up to \$100 million in an initial public offering... [more](#)

### Boehringer strengthens position in cancer immunology via acquisition

14th May 2020. [The Pharma Letter](#)

Boehringer Ingelheim has acquired Northern Biologics, a wholly-owned subsidiary of Canada... [more](#)

### Mediolanum buys French I-O company

7th May 2020. [The Pharma Letter](#)

Privately-held Italian pharma group Mediolanum Farmaceutici has acquired the French immuno-oncology... [more](#)

### Menarini nabs hematologic malignancy drug along with buy of Stemline

5th May 2020. [The Pharma Letter](#)

Privately-held pharma and diagnostics firm Menarini Group has announced a definitive agreement to acquire... [more](#)

## Corporate Action & Management

### Kitara Capital-backed Vivimed Labs hires FMCG veteran as CEO

8th May 2020. [VCCircle](#)

Specialty chemicals and pharmaceuticals supplier Vivimed Labs Ltd has appointed a veteran of the fast-moving consumer goods sector as its new chief executive officer.... [more](#)

Best Regards



Pooja Shah

Head-Research

Monal Capital (P) Limited

Tel.: +91-22-4976 1501 | 4976 1601 | 47081900 Mobile: +91 84548 07250 | [Email: pooja@monalcapital.com](mailto:pooja@monalcapital.com)

38-39, Sumtinath Estate, Behind Inorbit Mall, Off Link Road, Malad West, Mumbai : 400 064 India. [Website: www.monalcapital.com](http://www.monalcapital.com)

[Investment Banking - Debt Syndication](#) | [Corporate Finance](#) | [Bonds](#) | [Equity](#) | [Infrastructure](#) | [Real Estate](#) | [M&A](#) | [Stress Asset Solutions](#) | [Startup & VC Advisory](#)

Disclaimer: Information gathered & material used in this document is believed to be from reliable sources. Monal Capital however does not warrant the accuracy, reasonableness and/or completeness of any information. Monal Capital and any of its officer's directors, personnel and employees, shall not liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any way arising from the use of this material in any manner